Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  van den Engel, Natasja K ^a   Rüttinger, Dominik ^a   Rusan, Margareta ^a   Kammerer, Robert ^b   Zimmermann, Wolfgang ^a   Hatz, Rudolf A ^a   Winter, Hauke ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR CELL VACCINE; CANCER VACCINE; FREUND ADJUVANT; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN CELL; STOMACH CANCER; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CYTOTOXICITY; DISEASE MODEL; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECRETION; STOMACH TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; TUMOR CELL LINE; VACCINATION;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FREUND'S ADJUVANT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNITY; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LYMPH NODES; MICE; MICE, INBRED C57BL; STOMACH NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME; VACCINATION;

EID: 80052022750     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-140     Document Type: Article

References (56)

1. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2005, 54:209-241. 10.1016/j.critrevonc.2005.01.002, 15890270.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915. 10.1038/nm1100, 1435696, 15340416.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. 10.1056/NEJMoa1001294, 20818862.
4. Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002, 8:3394-3400.
5. Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D. A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 2004, 30:536-543. 10.1016/j.ejso.2004.03.009, 15135483.
6. Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A, Tanaka N, Itoh K, Harada M, Todo S. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 2007, 98:1113-1119. 10.1111/j.1349-7006.2007.00498.x, 17459063.
7. Poehlein CH, Ruttinger D, Ma J, Hu HM, Urba WJ, Fox BA. Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep 2005, 7:383-392. 10.1007/s11912-005-0066-1, 16091201.
8. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001, 61:3689-3697.
9. Ruttinger D, van den Engel NK, Winter H, Schlemmer M, Pohla H, Grutzner S, Wagner B, Schendel DJ, Fox BA, Jauch KW, Hatz RA. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med 2007, 5:43. 10.1186/1479-5876-5-43, 2020458, 17868452.
10. Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor. Clin Cancer Res 2008, 14:2833-2840. 10.1158/1078-0432.CCR-07-1742, 18451251.
11. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med 2000, 192:549-556. 10.1084/jem.192.4.549, 2193235, 10952724.
12. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol 1997, 9:339-346. 10.1006/smim.1997.0091, 9405262.
13. Hu HM, Poehlein CH, Urba WJ, Fox BA. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002, 62:3914-3919.
14. Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu HM. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 2003, 33:2123-2132. 10.1002/eji.200324034, 12884286.
15. Ma J, Poehlein CH, Jensen SM, LaCelle MG, Moudgil TM, Ruttinger D, Haley D, Goldstein MJ, Smith JW, Curti B, Ross H, Walker E, Hu HM, Urba WJ, Fox BA. Manipulating the host response to autologous tumour vaccines. Dev Biol (Basel) 2004, 116:93-107.
16. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868. 10.1182/blood-2004-06-2410, 15591121.
17. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344. 10.1002/eji.200324181, 14768038.
18. Salem ML, Kadima AN, El Naggar SA, Rubinstein MP, Chen Y, Gillanders WE, Cole DJ. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 2007, 30:40-53. 10.1097/01.cji.0000211311.28739.e3, 17198082.
19. Petrausch U, Jensen SM, Twitty C, Poehlein CH, Haley DP, Walker EB, Fox BA. Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. J Immunol 2009, 183:3682-3689. 10.4049/jimmunol.0900560, 2850273, 19692636.
20. Toge T. Effectiveness of immunochemotherapy for gastric cancer: a review of the current status. Semin Surg Oncol 1999, 17:139-143. 10.1002/(SICI)1098-2388(199909)17:2<139::AID-SSU9>3.0.CO;2-R, 10449686.
21. Kono K, Takahashi A, Amemiya H, Ichihara F, Sugai H, Iizuka H, Fujii H, Matsumoto Y. Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. Int J Cancer 2002, 98:216-220. 10.1002/ijc.10179, 11857411.
22. Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT, Jungbluth AA, Gnjatic S, Santiago D, Ritter G, Chen WF, Old LJ, Ji JF. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun 2004, 4:11.
23. Bolli M, Schultz-Thater E, Zajac P, Guller U, Feder C, Sanguedolce F, Carafa V, Terracciano L, Hudolin T, Spagnoli GC, Tornillo L. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study. Int J Cancer 2005, 115:960-966. 10.1002/ijc.20953, 15751033.
24. Chen Y, Wu K, Guo C, Liu C, Han S, Lin T, Ning X, Shi R, Shi Y, Fan D. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol Ther 2005, 4:308-312. 10.4161/cbt.4.3.1502, 15876863.
25. Nockel J, van den Engel NK, Winter H, Hatz RA, Zimmermann W, Kammerer R. Characterization of gastric adenocarcinoma cell lines established from CEA424/SV40 T antigen-transgenic mice with or without a human CEA transgene. BMC Cancer 2006, 6:57. 10.1186/1471-2407-6-57, 1421424, 16536871.
26. Thompson J, Epting T, Schwarzkopf G, Singhofen A, Eades-Perner AM, van der Putten H, Zimmermann W. A transgenic mouse line that develops early-onset invasive gastric carcinoma provides a model for carcinoembryonic antigen-targeted tumor therapy. Int J Cancer 2000, 86:863-869. 10.1002/(SICI)1097-0215(20000615)86:6<863::AID-IJC16>3.0.CO;2-4, 10842202.
27. Koike N, Pilon-Thomas S, Mule JJ. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother 2008, 31:402-412. 10.1097/CJI.0b013e31816cabbb, 18391755.
28. Vulliet R. Improved technique for the preparation of water-in-oil emulsions containing protein antigens. Biotechniques 1996, 20:797-800.
29. Meijer SL, Dols A, Hu HM, Chu Y, Romero P, Urba WJ, Fox BA. Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cell Immunol 2004, 227:93-102. 10.1016/j.cellimm.2004.01.006, 15135291.
30. Kammerer R, Stober D, Riedl P, Oehninger C, Schirmbeck R, Reimann J. Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells. J Immunol 2002, 168:108-117.
31. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ, Falk CS, Noessner E. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006, 12:718-725. 10.1158/1078-0432.CCR-05-0857, 16467081.
32. Salem ML, Diaz-Montero CM, Al Khami AA, El Naggar SA, Naga O, Montero AJ, Khafagy A, Cole DJ. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol 2009, 182:2030-2040. 10.4049/jimmunol.0801829, 3066095, 19201856.
33. Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother 2007, 56:1653-1665. 10.1007/s00262-007-0315-2, 17410360.
34. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009, 27:5911-5918. 10.1200/JCO.2009.23.3494, 2793039, 19805669.
35. Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol 2009, 46:448-456. 10.1016/j.molimm.2008.10.020, 2768258, 19046770.
36. Chamoto K, Takeshima T, Wakita D, Ohkuri T, Ashino S, Omatsu T, Shirato H, Kitamura H, Togashi Y, Nishimura T. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. Cancer Sci 2009, 100:934-939. 10.1111/j.1349-7006.2009.01114.x, 19245434.
37. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90:3539-3543. 10.1073/pnas.90.8.3539, 46336, 8097319.
38. Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 1996, 3:39-47.
39. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009, 69:4309-4318. 10.1158/0008-5472.CAN-08-4102, 3084614, 19435909.
40. Lipshy KA, Kostuchenko PJ, Hamad GG, Bland CE, Barrett SK, Bear HD. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma. Ann Surg Oncol 1997, 4:334-341. 10.1007/BF02303584, 9181234.
41. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003, 21:3343-3350. 10.1200/JCO.2003.07.005, 12947071.
42. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006, 13:555-562. 10.1038/sj.cgt.7700922, 16410826.
43. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990, 10:4239-4242. 360961, 2370865.
44. Daro E, Pulendran B, Brasel K, Teepe M, Pettit D, Lynch DH, Vremec D, Robb L, Shortman K, McKenna HJ, Maliszewski CR, Maraskovsky E. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000, 165:49-58.
45. Shi FS, Weber S, Gan J, Rakhmilevich AL, Mahvi DM. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther 1999, 6:81-88. 10.1038/sj.cgt.7700012, 10078967.
46. Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993, 53:5841-5844.
47. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001, 19:2666-2672. 10.1016/S0264-410X(00)00498-9, 11257407.
48. Moncada C, Torres V, Israel Y. Simple method for the preparation of antigen emulsions for immunization. J Immunol Methods 1993, 162:133-140. 10.1016/0022-1759(93)90415-4, 8509648.
49. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007, 18:226-232.
50. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163:5211-5218.
51. Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res 2003, 63:8384-8392.
52. LaCelle MG, Jensen SM, Fox BA. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res 2009, 15:6881-6890. 10.1158/1078-0432.CCR-09-1113, 2784281, 19903784.
53. Angulo I, las Heras FG, Garcia-Bustos JF, Gargallo D, Munoz-Fernandez MA, Fresno M. Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 2000, 95:212-220.
54. Angulo I, Jimenez-Diaz MB, Garcia-Bustos JF, Gargallo D, las Heras FG, Munoz-Fernandez MA, Fresno M. Candida albicans infection enhances immunosuppression induced by cyclophosphamide by selective priming of suppressive myeloid progenitors for NO production. Cell Immunol 2002, 218:46-58. 10.1016/S0008-8749(02)00521-X, 12470613.
55. Pelaez B, Campillo JA, Lopez-Asenjo JA, Subiza JL. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 2001, 166:6608-6615.
56. Bourquin C, von der BP, Zoglmeier C, Anz D, Sandholzer N, Suhartha N, Wurzenberger C, Denzel A, Kammerer R, Zimmermann W, Endres S. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model. J Immunol 2010, 185:2580-2588. 10.4049/jimmunol.0903231, 20644173.